Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis

Journal of Immunotherapy

Volumn 24, Issue 6, 2001, Pages 459-471

  Zisman, A ^a   Ng, C P ^a   Pantuck, A J ^a   Bonavida, B ^a   Belldegrun, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen independent; Apo2L TRAIL; Chemotherapy; Combination therapy; Prostate cancer; Synergy

Indexed keywords

ANDROGEN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; FAS LIGAND; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIZATION;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASES; CISPLATIN; DACTINOMYCIN; DEOXYCYTIDINE; DRUG SYNERGISM; ETOPOSIDE; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035196350     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200111000-00003     Document Type: Article

References (64)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
3. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
4. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells
5. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
6. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
7. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis
8. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
9. Apoptosis control by death and decoy receptors
10. Functional analysis of TRAIL receptors using monoclonal antibodies
11. TRAIL: A molecule with multiple receptors and control mechanisms
12. Safety and antitumor activity of recombinant soluble Apo2 ligand
13. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
14. Apoptosis by death factor
15. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer
16. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
17. Two TNF receptors
18. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
19. Fas-mediated apoptosis in primary cultured mouse hepatocytes
20. Lethal effect of the anti-Fas antibody in mice
21. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
22. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
23. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells
24. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D
25. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
26. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
27. APO2 ligand: A novel lethal weapon against malignant glioma?
28. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
29. Synergistic cytotoxicity and apoptosis by TRAIL and adriamycin against bladder cancer cells
30. An androgen independent, fluorescence tagged metastatic tumor model for hormone refractory metastatic prostate cancer
31. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells
32. CLl-GFP: An androgen-independent metastatic tumor model for prostate cancer
33. Features of apoptotic cells measured by flow cytometry
34. Synergy, additivism and antagonism in immunosuppression
35. A method for testing for synergy with any number of agents
36. Cancer statistics
37. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
38. Target to apoptosis: A hopeful weapon for prostate cancer
39. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen
40. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
41. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma
42. Molecular determinants of response to TRAIL in killing of normal and cancer cells
43. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
44. STAT1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs
45. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells
46. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
47. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis
48. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity
49. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis
50. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation
51. Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy
52. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs
53. Radiation and Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1
54. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
55. Actinomycin D-mediated sensitization of malignant oral cell lines to Fas-mediated cytotoxicity: Implication of p53 and FAP-1
56. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
57. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
58. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells
59. Actinomycin D: Drug concentration and action in mouse tissue and tumors
60. Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells
61. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
62. A quantitative assay for fragmented DNA in apoptotic cells
63. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis
64. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis